Relay Therapeutics Inc. (RLAY) News
Filter RLAY News Items
RLAY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RLAY News Highlights
- For RLAY, its 30 day story count is now at 9.
- Over the past 22 days, the trend for RLAY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RLAY are DRUG, NOV and TOP.
Latest RLAY News From Around the Web
Below are the latest news stories about RELAY THERAPEUTICS INC that investors may wish to consider to help them evaluate RLAY as an investment opportunity.
Wall Street Analysts See a 202.33% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?The consensus price target hints at a 202.3% upside potential for Relay Therapeutics, Inc. (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial IntelligenceWe’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare. |
Relay Therapeutics to Participate in Stifel 2023 Healthcare ConferenceCAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:50 p.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webc |
Relay Therapeutics Inc (RLAY) Reports Q3 2023 Financial Results: Revenue Surges to $25.2 MillionCompany's Cash Reserves Expected to Fund Operations into Second Half of 2026 |
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate HighlightsReported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runway by approximately 1 year Approximately $811 million in cash, cash equivalents and investments at end of Q3 2023, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Re |
Top 12 Medical AI CompaniesIn this article, we will take a look at the top 12 medical AI companies. To see more such companies, go directly to Top 5 Medical AI Companies. The healthcare and medical industry is one of the biggest beneficiaries of the AI boom. Over the past few years and months there has been a surge in […] |
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 2, 2023. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company tr |
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Companies Like Relay Therapeutics (NASDAQ:RLAY) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective programs, with plans to initiate RLY-2608 triplet combinations in HR+/HER2- breast cancer by YE 2023 Pipeline updates extend cash runway by 1 year into 2H2026 Relay Therapeutics to host a conference call today, October 12, at 5:30 p.m. ET BOSTON, Oct. 12, 2 |